# A1874

| | |
|---|---|
| **Cat. No.:** | HY-114305 |
| **CAS No.:** | 2064292-12-0 |
| **Molecular Formula:** | $C_{58}H_{62}Cl_3F_2N_9O_7S$ |
| **Molecular Weight:** | 1173.59 |
| **Target:** | PROTAC; Epigenetic Reader Domain |
| **Pathway:** | PROTAC; Epigenetics |
| **Storage:** | Please store the product under the recommended conditions in the COA. |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | A1874 is a nutlin-based and **BRD4-degrading PROTAC** with a **$DC_{50}$** of 32 nM (induce BRD4 degradation in cells). Effective in inhibiting many cancer cell lines proliferation[1]. |
| **$IC_{50}$ & Target** | BRD4 |
| **In Vitro** | Treatment of HCT116 cells of A1874 (0-10 μM, 24 hours) induces a dose-dependent knockdown of BRD4 levels, with near-maximum knockdown by 100 nmol/L and a maximum degradation (Dmax) of BRD4 of 98% of the levels in control (0.1% DMSO-treated) cells[1].<br>Treatment of HCT116 cells of A1874 (0-10 μM, 24 hours) increases p53 levels in the HCT116 cells and showed dose-dependent p53 stabilization[1].<br>**Western Blot Analysis[1]** |

| | |
|---|---|
| Cell Line: | HCT116 cells. |
| Concentration: | 0-10 μM. |
| Incubation Time: | 24 hours. |
| Result: | Induced a dosedependent knockdown of BRD4 levels, with near-maximum knockdown by 100 nM.<br>Increased p53 levels and showed dose-dependent p53 stabilization. |

## REFERENCES

[1]. Hines J, et al. MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53. Cancer Res. 2019 Jan 1;79(1):251-262.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA